Insider Selling: Phreesia, Inc. (NYSE:PHR) SVP Sells 640 Shares of Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) SVP Amy Beth Vanduyn sold 640 shares of the stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $26.89, for a total transaction of $17,209.60. Following the completion of the transaction, the senior vice president directly owned 129,180 shares of the company's stock, valued at approximately $3,473,650.20. The trade was a 0.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phreesia Trading Down 2.2%

Shares of PHR traded down $0.61 during trading hours on Thursday, hitting $27.09. 420,413 shares of the stock were exchanged, compared to its average volume of 577,443. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $30.53. The business has a 50-day moving average of $26.58 and a 200-day moving average of $26.43. The firm has a market capitalization of $1.61 billion, a P/E ratio of -36.60 and a beta of 0.72. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.95 and a quick ratio of 1.95.

Phreesia (NYSE:PHR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The business had revenue of $115.94 million for the quarter, compared to analysts' expectations of $115.00 million. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. The business's quarterly revenue was up 14.5% compared to the same quarter last year. On average, research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PHR. Wall Street Zen raised Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. DA Davidson raised Phreesia to a "strong-buy" rating in a research note on Tuesday. KeyCorp upped their price objective on Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a research note on Monday, July 14th. Truist Financial raised their price objective on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, May 29th. Finally, Canaccord Genuity Group reduced their target price on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a report on Thursday, May 29th. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $32.27.

Institutional Investors Weigh In On Phreesia

Several institutional investors and hedge funds have recently made changes to their positions in the business. Johnson Financial Group Inc. boosted its stake in Phreesia by 381.3% during the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock worth $28,000 after acquiring an additional 896 shares in the last quarter. Quarry LP increased its stake in Phreesia by 210.9% in the fourth quarter. Quarry LP now owns 2,835 shares of the company's stock valued at $71,000 after purchasing an additional 1,923 shares in the last quarter. KBC Group NV acquired a new position in shares of Phreesia during the first quarter valued at about $74,000. Farther Finance Advisors LLC boosted its position in shares of Phreesia by 9,375.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company's stock worth $86,000 after purchasing an additional 3,000 shares in the last quarter. Finally, CWM LLC boosted its position in shares of Phreesia by 994.9% during the 1st quarter. CWM LLC now owns 4,040 shares of the company's stock worth $103,000 after purchasing an additional 3,671 shares in the last quarter. Institutional investors own 92.10% of the company's stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.